The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Open accessAbstract
PURPOSE: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor ( EGFR) mutation-positive resected stage II-IIIA (N1-N2) non–small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results. METHODS: From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and EGFR-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was DFS (intention-to-treat [ITT] population). Secondary end points included OS, 3-, 5-year (y) DFS rates, and 5-year OS rate. Post hoc analysis was conducted for subsequent therapy data. RESULTS: Median follow-up was 80.0 months. Median OS (ITT) was 75.5 and 62.8 months with gefitinib and VP, respectively (hazard ratio [HR], 0.92; 95% CI, 0.62 to 1.36; P = .674); respective 5-year OS rates were 53.2% and 51.2% ( P = .784). Subsequent therapy was administered upon progression in 68.4% and 73.6% of patients receiving gefitinib and VP, respectively. Subsequent targeted therapy contributed most to OS (HR, 0.23; 95% CI, 0.14 to 0.38) compared with no subsequent therapy. Updated 3y DFS rates were 39.6% and 32. 5% with gefitinib and VP ( P = .316) and 5y DFS rates were 22. 6% and 23.2% ( P = .928), respectively. CONCLUSION: Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGoldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
Self-citationNCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, D. S., Wood, D. E., Aggarwal, C., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0059 · Cited by 956
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Shen, Y., Liu, Y.-Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 529
Self-citationKelly, K., Altorki, N. K., Eberhardt, W. E. E., O'Brien, M. E. R., Spigel, D. R., Crinò, L., Tsai, C.-M., Kim, J.-H., Cho, E. K., Hoffman, P. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8918 · Cited by 480
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
Eberhardt, W. E. E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., Westeel, V., Stahel, R., Felip, E., Peters, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv187 · Cited by 401
Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., Lin, S. H., Pass, H. I., Seth, R., Shepherd, F. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4401 · Cited by 368
Pisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 363
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
Burdett, S., Pignon, J. P., Tierney, J., Tribodet, H., Stewart, L., Le Pechoux, C., Aupérin, A., Le Chevalier, T., Stephens, R. J., Arriagada, R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011430 · Cited by 360
Yue, D., Xu, S., Wang, Q., Li, X., Shen, Y., Zhao, H., Chen, C., Mao, W., Liu, W., Liu, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30277-7 · Cited by 288
Self-citationZhong, W.-Z., Chen, K.-N., Chen, C., Gu, C.-D., Wang, J., Yang, X.-N., Mao, W.-M., Wang, Q., Qiao, G.-B., Cheng, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00075 · Cited by 268
Self-citationMauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Follow-up and Surveillance of the Patient With Lung Cancer After Curative-Intent Therapy
Colt, H. G., Murgu, S. D., Korst, R. J., Slatore, C. G., Unger, M., & Quadrelli, S. (2013) · Chest · doi:10.1378/chest.12-2365 · Cited by 223
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Jänne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00131 · Cited by 210
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100332 · Cited by 162
Wu, Y.-L. L. C., Herbst, R. S., Mann, H., Rukazenkov, Y., Marotti, M., & Tsuboi, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.004 · Cited by 111
Self-citationXu, L., Xi, J., Zhong, W., Mao, W., Wu, L., Shen, Y., Liu, Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.020 · Cited by 71
Self-citationOxnard, G. R., Janjigian, Y. Y., Arcila, M. E., Sima, C. S., Kass, S. L., Riely, G. J., Pao, W. J., Kris, M. G., Ladanyi, M., Azzoli, C. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1080 · Cited by 63
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
Cheng, H., Li, X., Wang, X., Chen, Z.-W., Wang, R., Zhong, H., Wu, T.-C., & Cao, Q. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.002 · Cited by 59
Self-citationZhou, Q. H., Song, Y., Zhang, X., Chen, G., Zhong, D., Yu, Z., Yu, P., Zhang, Y.-P., Chen, J., Hu, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3451-x · Cited by 31
Self-citationYuan, Y., Huang, Q., Gu, C., & Chen, H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.58 · Cited by 27
Cited by
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Self-citationRyad, N., Elmaaty, A. A., Selim, S., Almuhayawi, M. S., Al Jaouni, S. K., Abdel-Aziz, M. S., Alqahtani, A. S., Zaki, I., & Abdel Ghany, L. M. A. (2024) · RSC Advances · doi:10.1039/d4ra06712f · Cited by 13
Metadata
- Authors
- Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Wei, Y.-C., Liu, Y.-Y., Chen, C., Cheng, Y., Yin, R., Yang, F., Ren, S.-X., Li, X.-F., Li, J., Huang, C., Liu, Z.-D., Xu, S., Chen, K.-N., Xu, S.-D., Liu, L.-X., Yu, P., Wang, B.-H., Ma, H.-T., Yang, J.-J., Yan, H.-H., Yang, X.-N., Liu, S.-Y., Zhou, Q., & Wu, Y.-L.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-01
- Volume
- 39
- Issue
- 7
- Pages
- 713-722
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3111438285
- Cited by
- 273
- References
- 23
- FWCI
- 21.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.